Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon pathways
You must also meet one of these clinical criteria: BMI of 35 or higher (age 18+) BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease (stage 3a or higher) BMI of 27 or higher with pre-diabetes, a prior heart attack, stroke, or peripheral artery disease What Will It Cost
These products are shown as catalogue pairings only
Koudstaal T, Funke-Chambour M, Kreuter M, Molyneaux PL, Wijsenbeek MS
XBP1s-EDEM2 prevents the onset and development of HFpEF by ameliorating cardiac lipotoxicity